Literature DB >> 28437013

The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma.

Jiongke Wang1, Xin Jin2, Jiajia Liu1, Kui Zhao1, Hao Xu1, Jing Wen1, Lu Jiang1, Xin Zeng1, Jing Li1, Qianming Chen1.   

Abstract

OBJECTIVES: To investigate the expression and prognostic value of B7-H6 protein in oral squamous cell carcinoma tissues.
MATERIALS AND METHODS: A total of 50 oral squamous cell carcinoma samples, 10 oral leukoplakia (OLK) samples, and 17 normal controls were included in the analysis. The expression of B7-H6 in oral squamous cell carcinoma, OLK, and normal controls was evaluated by immunohistochemical assay.
RESULTS: The B7-H6 protein expression was significantly higher in oral squamous cell carcinoma tissues than that in normal oral mucosa. Furthermore, a significant relationship was found between the expression of B7-H6 and differentiation, but not with age, sex, tumor size, lymph metastasis, clinical stage, or recurrence. Further, the survival curves showed that B7-H6 was an independent prognostic factor of overall survival and disease-free survival in oral squamous cell carcinoma. Moreover, multivariate survival analysis by COX proportional hazard regression model revealed that the recurrence, differentiation, and expression of B7-H6 were related to the prognosis. Lastly, we verified the prognostic value of B7-H6 in oral squamous cell carcinoma.
CONCLUSIONS: B7-H6 may represent a new prognostic marker for oral squamous cell carcinoma.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B7-H6 protein; oral squamous cell carcinoma; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28437013     DOI: 10.1111/jop.12586

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

Review 1.  Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.

Authors:  Bita Amir Taghavi; Nazila Alizadeh; Hossein Saeedi; Noora Karim Ahangar; Afshin Derakhshani; Khalil Hajiasgharzadeh; Nicola Silvestris; Behzad Baradaran; Oronzo Brunetti
Journal:  Molecules       Date:  2022-05-31       Impact factor: 4.927

2.  Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.

Authors:  Qijie Zhao; Fuyan Hu; Zhangang Xiao; Mingxing Li; Xu Wu; Yueshui Zhao; Yuanlin Wu; Jianhua Yin; Ling Lin; Hanyu Zhang; Lingling Zhang; Chi Hin Cho; Jing Shen
Journal:  Cell Prolif       Date:  2018-07-12       Impact factor: 6.831

3.  B7 homolog 6 promotes the progression of cervical cancer.

Authors:  Ruimeng Guo; Guoyan Liu; Changying Li; Xuejing Liu; Yanying Xu; Weina Yang; Fang Wang
Journal:  Exp Ther Med       Date:  2021-05-18       Impact factor: 2.447

4.  B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

Authors:  Siyuan Yang; Lei Yuan; Yanfang Wang; Mingxia Zhu; Jing Wang; Xiaoyan Ke
Journal:  Onco Targets Ther       Date:  2020-06-18       Impact factor: 4.147

Review 5.  The Natural Cytotoxicity Receptors in Health and Disease.

Authors:  Alexander David Barrow; Claudia Jane Martin; Marco Colonna
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

6.  Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.

Authors:  Xiuqin Zhang; Weiguo Xie; Zhiqiang Wang; Shu Song; Yan Qin; Fang Zhang; Fangfang Chen; Liming Cai
Journal:  Ann Transl Med       Date:  2020-05

7.  Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer.

Authors:  Gloria Yareli Gutierrez-Silerio; Ramon Antonio Franco-Topete; Jesse Haramati; Eduardo Miguel Navarrete-Medina; Jorge Gutierrez-Franco; Miriam Ruth Bueno-Topete; Blanca Estela Bastidas-Ramirez; Martha Eloisa Ramos-Marquez; Susana Del Toro-Arreola
Journal:  BMC Immunol       Date:  2020-03-06       Impact factor: 3.615

Review 8.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.